In conclusion, we present compelling biological evidence demonstrating a functional capacity of TUSC2 gene restoration to sensitize wild type EGFR NSCLC cells to erlotinib treatment, in vitro and in vivo. This evidence concerns the gene TUSC2 and non-small cell lung carcinoma.